250 related articles for article (PubMed ID: 33501934)
1. Genetic Background of Mesalamine-induced Fever and Diarrhea in Japanese Patients with Inflammatory Bowel Disease.
Suzuki K; Kakuta Y; Naito T; Takagawa T; Hanai H; Araki H; Sasaki Y; Sakuraba H; Sasaki M; Hisamatsu T; Motoya S; Matsumoto T; Onodera M; Ishiguro Y; Nakase H; Andoh A; Hiraoka S; Shinozaki M; Fujii T; Katsurada T; Kobayashi T; Fujiya M; Otsuka T; Oshima N; Suzuki Y; Sato Y; Hokari R; Noguchi M; Ohta Y; Matsuura M; Kawai Y; Tokunaga K; Nagasaki M; Kudo H; Minegishi N; Okamoto D; Shimoyama Y; Moroi R; Kuroha M; Shiga H; Li D; McGovern DPB; Kinouchi Y; Masamune A;
Inflamm Bowel Dis; 2022 Jan; 28(1):21-31. PubMed ID: 33501934
[TBL] [Abstract][Full Text] [Related]
2. Ulcerative colitis flair induced by mesalamine suppositories hypersensitivity.
Ding H; Liu XC; Mei Q; Xu JM; Hu XY; Hu J
World J Gastroenterol; 2014 Apr; 20(13):3716-8. PubMed ID: 24707159
[TBL] [Abstract][Full Text] [Related]
3. Significance of 5-Aminosalicylic Acid Intolerance in the Clinical Management of Ulcerative Colitis.
Mikami Y; Tsunoda J; Suzuki S; Mizushima I; Kiyohara H; Kanai T
Digestion; 2023; 104(1):58-65. PubMed ID: 36366816
[TBL] [Abstract][Full Text] [Related]
4. Diarrhea as a side effect of mesalamine treatment for inflammatory bowel disease.
Goldstein F; DiMarino AJ
J Clin Gastroenterol; 2000 Jul; 31(1):60-2. PubMed ID: 10914779
[TBL] [Abstract][Full Text] [Related]
5. Multicenter survey on mesalamine intolerance in patients with ulcerative colitis.
Hiraoka S; Fujiwara A; Toyokawa T; Higashi R; Moritou Y; Takagi S; Matsueda K; Suzuki S; Miyaike J; Inokuchi T; Takahara M; Kato J; Okada H
J Gastroenterol Hepatol; 2021 Jan; 36(1):137-143. PubMed ID: 32525567
[TBL] [Abstract][Full Text] [Related]
6. The culprit of mesalamine intolerance: case series and literature review.
Xie C; Quan R; Hong F; Zou K; Yan W; Fu Y
BMC Gastroenterol; 2019 Jul; 19(1):138. PubMed ID: 31366329
[TBL] [Abstract][Full Text] [Related]
7. Isolated fever induced by mesalamine treatment.
Slim R; Amara J; Nasnas R; Honein K; Jaoude JB; Yaghi C; Daniel F; Sayegh R
World J Gastroenterol; 2013 Feb; 19(7):1147-9. PubMed ID: 23467507
[TBL] [Abstract][Full Text] [Related]
8. Mesalamine treatment mimicking relapse in a child with ulcerative colitis.
Hojsak I; Pavić AM; Kolaček S
World J Pediatr; 2014 Nov; 10(4):371-3. PubMed ID: 24974209
[TBL] [Abstract][Full Text] [Related]
9. Mesalamine in the Initial Therapy of Ulcerative Colitis.
Chibbar R; Moss AC
Gastroenterol Clin North Am; 2020 Dec; 49(4):689-704. PubMed ID: 33121689
[TBL] [Abstract][Full Text] [Related]
10. The effect of mesalamine and nicotine in the treatment of inflammatory bowel disease.
Bonapace CR; Mays DA
Ann Pharmacother; 1997; 31(7-8):907-13. PubMed ID: 9220055
[TBL] [Abstract][Full Text] [Related]
11. NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study.
Kakuta Y; Kawai Y; Okamoto D; Takagawa T; Ikeya K; Sakuraba H; Nishida A; Nakagawa S; Miura M; Toyonaga T; Onodera K; Shinozaki M; Ishiguro Y; Mizuno S; Takahara M; Yanai S; Hokari R; Nakagawa T; Araki H; Motoya S; Naito T; Moroi R; Shiga H; Endo K; Kobayashi T; Naganuma M; Hiraoka S; Matsumoto T; Nakamura S; Nakase H; Hisamatsu T; Sasaki M; Hanai H; Andoh A; Nagasaki M; Kinouchi Y; Shimosegawa T; Masamune A; Suzuki Y;
J Gastroenterol; 2018 Sep; 53(9):1065-1078. PubMed ID: 29923122
[TBL] [Abstract][Full Text] [Related]
12. Cancer risk and chemoprevention in Chinese inflammatory bowel disease patients: a population-based cohort study.
Mak JWY; So J; Tang W; Yip TCF; Leung WK; Li M; Lo FH; Ng KM; Sze SF; Leung CM; Tsang SWC; Shan EHS; Chan KH; Lam BCY; Hui AJ; Chow WH; Chan FKL; Ng SC
Scand J Gastroenterol; 2020 Mar; 55(3):279-286. PubMed ID: 32119788
[No Abstract] [Full Text] [Related]
13. Aminosalicylates for induction of remission or response in Crohn's disease.
Lim WC; Wang Y; MacDonald JK; Hanauer S
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD008870. PubMed ID: 27372735
[TBL] [Abstract][Full Text] [Related]
14. Effect of tumor necrosis factor-α inhibitors on drug-induced pancreatitis in inflammatory bowel disease.
Stobaugh DJ; Deepak P
Ann Pharmacother; 2014 Oct; 48(10):1282-7. PubMed ID: 24982311
[TBL] [Abstract][Full Text] [Related]
15. Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease.
Heap GA; So K; Weedon M; Edney N; Bewshea C; Singh A; Annese V; Beckly J; Buurman D; Chaudhary R; Cole AT; Cooper SC; Creed T; Cummings F; de Boer NK; D'Inca R; D'Souza R; Daneshmend TK; Delaney M; Dhar A; Direkze N; Dunckley P; Gaya DR; Gearry R; Gore S; Halfvarson J; Hart A; Hawkey CJ; Hoentjen F; Iqbal T; Irving P; Lal S; Lawrance I; Lees CW; Lockett M; Mann S; Mansfield J; Mowat C; Mulgrew CJ; Muller F; Murray C; Oram R; Orchard T; Parkes M; Phillips R; Pollok R; Radford-Smith G; Sebastian S; Sen S; Shirazi T; Silverberg M; Solomon L; Sturniolo GC; Thomas M; Tremelling M; Tsianos EV; Watts D; Weaver S; Weersma RK; Wesley E; Holden A; Ahmad T
J Crohns Colitis; 2016 Feb; 10(2):149-58. PubMed ID: 26619893
[TBL] [Abstract][Full Text] [Related]
16. Impact of Low Immunoglobulin G Levels on Disease Outcomes in Patients with Inflammatory Bowel Diseases.
Horton N; Wu X; Philpott J; Garber A; Achkar JP; Brzezinski A; Lashner BA; Shen B
Dig Dis Sci; 2016 Nov; 61(11):3270-3277. PubMed ID: 27619393
[TBL] [Abstract][Full Text] [Related]
17. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Feagan BG; Macdonald JK
Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
[TBL] [Abstract][Full Text] [Related]
18. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Wang Y; Parker CE; Bhanji T; Feagan BG; MacDonald JK
Cochrane Database Syst Rev; 2016 Apr; 4(4):CD000543. PubMed ID: 27101467
[TBL] [Abstract][Full Text] [Related]
19. Mesalamine-induced granulomatous hepatitis.
Braun M; Fraser GM; Kunin M; Salamon F; Tur-Kaspa R
Am J Gastroenterol; 1999 Jul; 94(7):1973-4. PubMed ID: 10406274
[TBL] [Abstract][Full Text] [Related]
20. Mesalamine intolerance mimics symptoms of active inflammatory bowel disease.
Iofel E; Chawla A; Daum F; Markowitz J
J Pediatr Gastroenterol Nutr; 2002 Jan; 34(1):73-6. PubMed ID: 11753169
[No Abstract] [Full Text] [Related]
[Next] [New Search]
